IQVIA Holdings Inc. is a global provider of analytics, technology, and clinical research services to the life sciences industry. The company operates in multiple countries and has a market capitalization of $41.28 billion.

Analysts expect IQVIA to report a profit of $3.13 per share in Q4, up 7.9% YOY. For fiscal year 2025, diluted EPS is projected to grow by 5.3% annually to $10.79.

IQVIA’s stock has underperformed the market over the past year but outperformed in the last six months, gaining 48%. The company has also outperformed its sector.

IQVIA recently partnered with Amazon Web Services to improve healthcare analytics using AI. The company’s Q3 results for fiscal 2025 exceeded expectations, with revenue up 5.2% YOY.

Analysts have a “Strong Buy” rating on IQVIA, with a mean price target of $255.60 implying a 6.1% upside. The stock also has one “Moderate Buy” and five “Hold” ratings.

Read more at Yahoo Finance: What You Need To Know Ahead of IQVIA’s Earnings Release